Amneal Pharmaceuticals held a special meeting on July 31, 2026, where stockholders approved the acquisition of 100% of Kashiv BioSciences from its equityholders. The transaction involves issuing 28,942,108 shares of Class A common stock to the sellers and is expected to close in the second half of 2026, pending remaining conditions including regulatory approvals. Amneal Pharmaceuticals operates in the pharmaceutical industry, specializing in generic and specialty drugs.

Amneal Pharmaceuticals reported second quarter 2026 results with net revenue of $796 million, a 10% increase year-over-year. GAAP net income rose 157% to $58 million, or $0.18 diluted EPS, while adjusted EBITDA increased 12% to $206 million and adjusted diluted EPS reached $0.30. The company raised its full-year 2026 guidance for net revenue to $3.10–$3.20 billion and adjusted EBITDA to $750–$780 million. Additionally, Amneal announced a debt repricing of its $2.084 billion Term Loan B in July 2026, reducing the interest spread by 50 basis points to generate approximately $12 million in annual savings. The firm operates as a diversified global biopharmaceutical company specializing in complex generics, specialty medicines, and biosimilars.